Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
Previous Symbol
CUSIP03152W10
Phone609-662-2000
Debt
Debt-to-Equity Ratio0.78
Current Ratio9.12
Quick Ratio9.03
Price-To-Earnings
Trailing P/E Ratio-3.43
Forward P/E Ratio-8.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.93 million
Price / Sales51.31
Cash FlowN/A
Price / CashN/A
Book Value$2.12 per share
Price / Book4.72
Profitability
EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-463.82%
Return on Equity-52.03%
Return on Assets-30.40%
Miscellaneous
Employees325
Outstanding Shares189,290,000
Market Cap$2.03 billion
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings data on Monday, November, 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.04. The biopharmaceutical company earned $20.60 million during the quarter, compared to the consensus estimate of $23.56 million. Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. Amicus Therapeutics's revenue for the quarter was up 89.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.41) EPS. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-90 million, compared to the consensus revenue estimate of $89.85 million.
What price target have analysts set for FOLD?
5 brokerages have issued twelve-month target prices for Amicus Therapeutics' shares. Their predictions range from $12.00 to $31.00. On average, they anticipate Amicus Therapeutics' share price to reach $20.40 in the next twelve months. This suggests a possible upside of 103.8% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
Has Amicus Therapeutics been receiving favorable news coverage?
Headlines about FOLD stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amicus Therapeutics earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the near term.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 26,372,583 shares, an increase of 0.9% from the October 15th total of 26,141,775 shares. Based on an average daily volume of 2,764,033 shares, the days-to-cover ratio is presently 9.5 days. Currently, 14.4% of the shares of the company are sold short. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), SAGE Therapeutics (SAGE), Amarin (AMRN), United Therapeutics (UTHR), Loxo Oncology (LOXO) and Agios Pharmaceuticals (AGIO).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 51)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 42)
- Mr. William D. Baird III, Chief Financial Officer (Age 46)
- Ms. Ellen S. Rosenberg, Gen. Counsel & Corp. Sec. (Age 55)
- Dr. Jay A. Barth, Chief Medical Officer (Age 54)
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (10.93%), BlackRock Inc. (8.65%), FMR LLC (7.11%), Jennison Associates LLC (5.32%), Janus Henderson Group PLC (4.65%) and Redmile Group LLC (4.44%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which major investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Franklin Resources Inc., Allianz Asset Management GmbH, Morgan Stanley, Wexford Capital LP, Russell Investments Group Ltd., AQR Capital Management LLC and Jennison Associates LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which major investors are buying Amicus Therapeutics stock?
FOLD stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc., Perceptive Advisors LLC, AXA, Janus Henderson Group PLC, Sphera Funds Management LTD., Pictet Asset Management Ltd. and Sofinnova Ventures Inc. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $10.01.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.03 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
